Actively Recruiting
A Study Of Deep Learning For Echo Analysis, Tracking, And Evaluation
Led by Mayo Clinic · Updated on 2026-04-16
10040000
Participants Needed
1
Research Sites
100 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to deploy and evaluate informational AI-Echo algorithms that assist echo clinicians in interpreting core echocardiographic parameters (e.g., LV/RV size and function, valvular disease severity) and stratifying disease progression risk. The primary outcome is clinician usability, interpretive consistency, and workflow integration. Second, we will conduct a pragmatic, stepped-wedge clinical trial with multiple arms evaluating diagnostic AI-Echo algorithms designed to identify specific cardiovascular diseases- such as genetic cardiomyopathy, ischemic heart disease, and cardiac amyloidosis-and assess whether AI deployment increases diagnostic testing and shortens time to diagnosis. Trials will be conducted using EHR-based notification systems with cluster-level randomization.
CONDITIONS
Official Title
A Study Of Deep Learning For Echo Analysis, Tracking, And Evaluation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinicians who order, perform, and interpret echocardiograms and act on results caring for patients aged 18 years or older.
- Patients undergoing comprehensive transthoracic echocardiography (TTE) at participating Mayo Clinic sites.
- AI-Echo analysis indicating high risk for genetic cardiomyopathy, ischemic cardiomyopathy, cardiac amyloidosis, or hypertrophic cardiomyopathy based on defined thresholds.
- High-risk scores determined to maximize sensitivity and maintain positive predictive value for clinical deployment.
You will not qualify if you...
- Patients with studies performed within the past 2 years at a Mayo site for the respective disease arm.
- Patients with known or suspected diagnosis of genetic cardiomyopathy under evaluation, on hospice care, or with expected non-cardiac life expectancy less than 1 year.
- Patients with known coronary artery disease, prior myocardial infarction, revascularization procedures, ischemic testing within past 12 months, on hospice care, or with expected non-cardiac life expectancy less than 1 year.
- Patients with prior amyloid-specific testing or biopsy-proven systemic amyloidosis, on hospice care, or with expected non-cardiac life expectancy less than 1 year.
- Patients with known hypertrophic cardiomyopathy diagnosis before the index TTE, prior septal reduction therapy, on hospice care, or with expected non-cardiac life expectancy less than 1 year.
- Patients who have opted out of institutional and state research authorizations.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mayo Clinic
Rochester, Minnesota, United States, 55905
Actively Recruiting
Research Team
T
Tim Poterucha, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here